[0021] Another important aspect of the present invention is to further improve paracellular transport of semaglutide across nasal mucosa by tight junction modulating agents
Tirzepatide is generally suitable for adults in San Diego who are overweight or obese and have not seen significant progress with diet and exercise alone
Experts recommend high-calorie diets (around 3540 kcal per kilogram of body weight per day), often with a high-fat content, which might offer some protective effects on nerve cells (Guillemin et al., 2022)
not safety or efficacy guidance
Currently, there is an ongoing randomised double-masked placebo-controlled trial, the SUMMIT trial, studying the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, versus placebo in HFpEF patients with obesity (NCT04847557)
Here are some potential benefits of switching: More and faster weight loss Better blood glucose control, especially when weight loss has plateaued Drug availability, as tirzepatide may be easier to find right now Lower cost, with tirzepatide being about $300 less per month without insurance Risks and Potential Drawbacks of Switching Switching from semaglutide to tirzepatide can come with potential risks and drawbacks beyond just the common side effects
